Molecular targeted therapy for biliary tract malignancy: defining the target.
作者信息
Fisher Sarah B, Fisher Kevin E, Maithel Shishir K
机构信息
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Department of Pathology and Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
出版信息
Hepatobiliary Surg Nutr. 2012 Dec;1(1):53-4. doi: 10.3978/j.issn.2304-3881.2012.10.02.
Abstract
摘要
相似文献
1
Molecular targeted therapy for biliary tract malignancy: defining the target.胆管恶性肿瘤的分子靶向治疗：确定靶点
Hepatobiliary Surg Nutr. 2012 Dec;1(1):53-4. doi: 10.3978/j.issn.2304-3881.2012.10.02.
2
Risk of subsequent biliary malignancy in patients undergoing cyst excision for congenital choledochal cysts.先天性胆总管囊肿患者行囊肿切除术后发生胆道恶性肿瘤的风险。
J Gastroenterol Hepatol. 2013 Feb;28(2):243-7. doi: 10.1111/j.1440-1746.2012.07260.x.
3
Biliary tract cancers: understudied and poorly understood.胆道癌：研究不足且了解甚少。
J Clin Oncol. 2015 Jun 1;33(16):1845-8. doi: 10.1200/JCO.2014.59.7591. Epub 2015 Apr 27.
4
Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling.胆道癌：流行病学、放射治疗及分子特征分析
Am Soc Clin Oncol Educ Book. 2016;35:e194-203. doi: 10.1200/EDBK_160831.
5
A Series of Biliary Tract Cancer With Coexistent Non-biliary Second Malignancy From Sub-Himalayan Region of India.来自印度次喜马拉雅地区的一系列伴有共存非胆道第二原发恶性肿瘤的胆道癌。
Cureus. 2021 Feb 18;13(2):e13415. doi: 10.7759/cureus.13415.
6
Targeted therapy for biliary tract cancer.胆管癌的靶向治疗。
Cancers (Basel). 2011 May 3;3(2):2243-54. doi: 10.3390/cancers3022243.
7
Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.胆管癌发生中的分子靶点及其治疗意义
Oncologist. 2015 Jul;20(7):742-51. doi: 10.1634/theoncologist.2014-0442. Epub 2015 May 29.
8
Is there any place for novel agents in treating biliary tract cancer?新型药物在胆管癌治疗中有一席之地吗？
Med Oncol. 2021 Feb 4;38(2):19. doi: 10.1007/s12032-021-01463-4.
9
Second-line therapies in advanced biliary tract cancers.二线治疗方案在晚期胆道癌中的应用。
Lancet Oncol. 2020 Jan;21(1):e29-e41. doi: 10.1016/S1470-2045(19)30733-8.
10
Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.罕见癌症，罕见改变：胆道癌中的 NTRK 融合案例。
Expert Opin Investig Drugs. 2021 Apr;30(4):401-409. doi: 10.1080/13543784.2021.1896703. Epub 2021 Mar 24.
引用本文的文献
1
Differential Diagnosis of Immunoglobulin G4-associated Cholangitis From Cholangiocarcinoma.免疫球蛋白G4相关性胆管炎与胆管癌的鉴别诊断
J Clin Gastroenterol. 2016 Jul;50(6):501-5. doi: 10.1097/MCG.0000000000000509.
2
Retrospective evaluation of endoscopic stenting of combined malignant common bile duct and gastric outlet-duodenum obstructions.恶性胆总管合并胃出口-十二指肠梗阻内镜支架置入术的回顾性评估
Exp Ther Med. 2014 Oct;8(4):1173-1177. doi: 10.3892/etm.2014.1899. Epub 2014 Aug 11.
3
A novel PTEN gene promoter mutation and untypical Cowden syndrome.一个新的 PTEN 基因启动子突变与非典型考登综合征。
Chin J Cancer Res. 2013 Jun;25(3):306-11. doi: 10.3978/j.issn.1000-9604.2013.06.02.
4
Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.表皮生长因子受体过表达是甲状腺乳头状癌不良病理特征的标志物。
J Surg Res. 2013 Nov;185(1):217-24. doi: 10.1016/j.jss.2013.05.003. Epub 2013 May 23.
本文引用的文献
1
Biliary tract carcinomas: from chemotherapy to targeted therapy.胆道癌：从化疗到靶向治疗。
Crit Rev Oncol Hematol. 2013 Feb;85(2):136-48. doi: 10.1016/j.critrevonc.2012.06.006. Epub 2012 Jul 17.
2
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.吉西他滨和奥沙利铂联合或不联合厄洛替尼治疗晚期胆道癌的多中心、开放标签、随机、3 期研究。
Lancet Oncol. 2012 Feb;13(2):181-8. doi: 10.1016/S1470-2045(11)70301-1. Epub 2011 Dec 20.
3
Biliary-tract cancer: improving therapy by adding molecularly targeted agents.胆道癌：通过添加分子靶向药物改善治疗
Lancet Oncol. 2012 Feb;13(2):118-9. doi: 10.1016/S1470-2045(11)70329-1. Epub 2011 Dec 20.
4
Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.联合生物制剂和化疗治疗胆管癌。
Expert Rev Anticancer Ther. 2011 Apr;11(4):589-600. doi: 10.1586/era.11.17.
5
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
6
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.顺铂联合吉西他滨与吉西他滨治疗胆管癌。
N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.
7
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.K-ras突变与晚期结直肠癌患者从西妥昔单抗治疗中获益的关系
N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.
8
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
9
Cetuximab for the treatment of colorectal cancer.西妥昔单抗用于治疗结直肠癌。
N Engl J Med. 2007 Nov 15;357(20):2040-8. doi: 10.1056/NEJMoa071834.
10
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.厄洛替尼联合吉西他滨与吉西他滨单药治疗晚期胰腺癌患者的比较：加拿大国家癌症研究所临床试验组的一项III期试验
J Clin Oncol. 2007 May 20;25(15):1960-6. doi: 10.1200/JCO.2006.07.9525. Epub 2007 Apr 23.
Zotero 插件